Pricing Log in Create free account
Friday 6 November 2026 Export RVMD’s income statement to Excel — free account

Revolution Medicines, Inc.

RVMD Healthcare Biotechnology

Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.

Revenue
+1,188.7%
EPS
−18.0%
Free cash flow
−99.1%
Total debt
+322.7%

Quarter to September 2026, against a year earlier

192.35 14.70 +8.27%
Market cap
$38.1B
P/E
0.0×
Fwd P/E
−11.9×
Dividend yield
—
F-score
4/9
Altman Z
7.73
Beneish M
−4.29
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Revolution Medicines, Inc. 10-K filed Feb 25, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 4:11 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1A, Risk Factors, against the 10-K filed Feb 26, 2025: 38 added · 27 removed · 110 modified; 1 with only figures updated; 1 moved without change

175 more changes in this Item, word by word, in Powerpack.